CSS
AMAM

Cubist Systematic Strategies’s Ambrx Biopharma Inc AMAM Stock Holding History

Cubist Systematic Strategies’s Portfolio AMAM Stock Details AMAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-17,905
Closed -$40.6K – 4611
2022
Q4 		$40.6K Buy
+17,905
New +$20.5K ﹤0.01% 3932

Other funds holding AMAM

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Cubist Systematic Strategies's AMAM Position: Q1 2023 in Review

Cubist Systematic Strategies sold out of Ambrx Biopharma Inc (AMAM) in Q1 2023, closing a stake of 17,905 shares — an estimated $40.6K sold.

Cubist Systematic Strategies first reported a position in AMAM in Q4 2022 and held it in 1 quarter. The position peaked at $40.6K in Q4 2022. 30 funds tracked by Wall St. Rank hold AMAM as of Q1 2023.

  • Cubist Systematic Strategies reported no remaining Ambrx Biopharma Inc position as of Q1 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 17,905 Ambrx Biopharma Inc shares in Q1 2023, an estimated $40.6K.
  • Cubist Systematic Strategies first reported a position in Ambrx Biopharma Inc in Q4 2022 and held it in 1 quarter.
  • Cubist Systematic Strategies's Ambrx Biopharma Inc position peaked at $40.6K in Q4 2022.
  • 30 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q1 2023.

Based on Cubist Systematic Strategies's 13F filing for Q1 2023, filed 15 May 2023.